ŘIHÁČEK, Michal, Ivan ŘIHÁČEK, Lenka ZDRAŽILOVÁ DUBSKÁ a Kateřina PILÁTOVÁ. Methotrexate update 2014: 70 years in autoimmunity and cancer treatment. Česko-slovenská pediatrie. Praha: Česká lékařská společnost J.E. Purkyně, 2014, roč. 69, č. 3, s. 161-167. ISSN 0069-2328. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1195851, author = {Řiháček, Michal and Řiháček, Ivan and Zdražilová Dubská, Lenka and Pilátová, Kateřina}, article_location = {Praha}, article_number = {3}, keywords = {methotrexate; autoimmunity; neoplasms; biological markers; toxicity; adverse effects}, language = {eng}, issn = {0069-2328}, journal = {Česko-slovenská pediatrie}, title = {Methotrexate update 2014: 70 years in autoimmunity and cancer treatment}, volume = {69}, year = {2014} }
TY - JOUR ID - 1195851 AU - Řiháček, Michal - Řiháček, Ivan - Zdražilová Dubská, Lenka - Pilátová, Kateřina PY - 2014 TI - Methotrexate update 2014: 70 years in autoimmunity and cancer treatment JF - Česko-slovenská pediatrie VL - 69 IS - 3 SP - 161-167 EP - 161-167 PB - Česká lékařská společnost J.E. Purkyně SN - 00692328 KW - methotrexate KW - autoimmunity KW - neoplasms KW - biological markers KW - toxicity KW - adverse effects N2 - Immunosupressive and antineoplastic activity brought methotrexate to its clinical use many years ago. Although modern antitumour and antiinflammatory drugs and new antifolates have challenged methotrexate, its use in rheumatoid arthritis and in some types of pediatric and adult malignancies remains a gold standard. The principal main mechanism of action of methotrexate is competitive inhibition of dihydrofolate reductase. Recently, other pharmacodynamic effects have been described. Potent inflammation inducers such as leukotriene-B4 and polyamine synthesis were found to be reduced by methotrexate treatment. Jun N-terminal kinase and B cell lymphoma 2 gene are downregulated by methotrexate. Its metabolite, 7-hydroxymethotrexate and also its intracellular polyglutamated forms show a different spectrum of inhibitory activity as well as potency towards dihydrofolate reductase and other enzymes. In this review, we summarize recent information data on methotrexate in both fields of its use, oncology and rheumatology. We also discuss new biomarkers of toxicity for further improvement of therapeutic protocols. ER -
ŘIHÁČEK, Michal, Ivan ŘIHÁČEK, Lenka ZDRAŽILOVÁ DUBSKÁ a Kateřina PILÁTOVÁ. Methotrexate update 2014: 70 years in autoimmunity and cancer treatment. \textit{Česko-slovenská pediatrie}. Praha: Česká lékařská společnost J.E. Purkyně, 2014, roč.~69, č.~3, s.~161-167. ISSN~0069-2328.
|